X4 Pharmaceuticals Inc (XFOR) 13F Investor Activity Report (Q2 2026)

XFOR ranks #4836 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

XFOR is a top-conviction position for Empery Asset Management, LP — at 37.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in XFOR belongs to Morgan Stanley, but the position matters far more to Empery Asset Management, LP, who has 37.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

XFOR is up 7.8% today, and institutions have been net buyers of $44.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

XFOR reported a net loss of $90.1M over the trailing twelve months.

• Not yet profitable — net loss of $90.1M over the trailing twelve months
• Revenue declined 51.6% year over year
• Net income improved year over year, from -$102.0M to -$90.1M
• Operating cash flow was negative, using $85.6M in cash
• Current ratio of 10.16x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.56x equity — within a conventional range